NEUROCRINE BIOSCIENCES INC Other Current Liabilities
NEUROCRINE BIOSCIENCES INC (NBIX) had Other Current Liabilities of $66.20 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-07-31
- 2026-06-30: Other Liabilities, Current $66.20M.
- 2026-03-31: Other Liabilities, Current $58.70M.
- 2025-12-31: Other Liabilities, Current $69.10M.
- 2025-09-30: Other Liabilities, Current $53.70M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $66.20M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $58.70M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $69.10M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $53.70M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $56.80M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $47.70M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $46.10M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $37.00M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $40.00M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $36.70M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $35.90M 10-K · filed 2025-02-10 | |
| 2023-09-30 | $18.70M 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $21.20M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $18.40M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $20.70M 10-K · filed 2024-02-09 | |
| 2022-09-30 | $18.10M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $20.00M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $17.60M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $20.00M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $20.00M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $22.00M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $18.10M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $17.80M 10-K · filed 2022-02-11 | |
| 2020-09-30 | $15.50M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $16.40M 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $14.40M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $15.20M 10-K · filed 2021-02-05 | $15.20M 10-K · filed 2020-02-07 |
| 2019-09-30 | $13.29M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $5.56M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $3.72M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $1.86M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $731.00K 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $731.00K 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $85.00K 10-Q · filed 2018-04-30 | |
| 2017-12-31 | $906.00K 10-K · filed 2019-02-08 | $113.00K 10-K · filed 2018-02-13 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |